Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCeapro

Ceapro

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
6.21 CAD 0.12 ( 1.97%)
Last update at 2024-06-25T13:30:00Z
VOLUME
600
Market Cap
12.92M

Momentum Score

…

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
6.01
Low
6.21
High
52 Week Price Range
0.15
Low
0.73
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
6.09
Dividend Yield
-
Revenue TTM
11.30M
Revenue Per Share
0.14
Gross Profit TTM
9.69M
Debt / Equity
-
ROE
-9.09%
Net Debt
-
ROCE
15.43%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 5.78M 2.62M 1.86M -1.14M -0.92M
Net income 4.40M 2.84M 1.86M -1.13M -0.32M
Selling general administrative 3.73M 3.29M 3.39M 3.38M 3.23M
Gross profit 11.02M 9.69M 7.62M 5.45M 6.14M
Reconciled depreciation 1.91M 1.88M 1.84M 1.83M 0.58M
Ebit - 2.62M 2.35M -0.33M 0.25M
Ebitda 7.82M 4.65M 3.87M 0.90M -0.29M
Operating income 5.50M 2.62M 2.35M -0.33M 0.97M
Interest expense 0.13M 0.15M 0.18M 0.20M 0.05M
Tax provision 1.38M -0.22M 0.00M -0.00M -0.61M
Net interest income -0.18M -0.21M -0.23M -0.26M -0.10M
Income tax expense - -0.22M - -0.00M -0.61M
Total revenue 18.84M 17.20M 15.12M 12.88M 11.59M
Total operating expenses 13.34M 14.57M 12.77M 13.21M 10.62M
Cost of revenue 7.82M 7.51M 7.50M 7.43M 5.45M
Total other income expense net 0.46M 0.20M -0.26M -0.55M -1.79M
Net income from continuing ops 4.40M 2.84M 1.86M -1.13M -0.32M
Net income applicable to common shares - 2.84M 1.86M -1.13M -0.32M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 37.73M 30.53M 29.22M 27.27M 25.32M
Intangible assets 0.01M 0.02M 0.02M 0.02M 0.02M
Total liab 5.45M 3.33M 4.91M 4.96M 2.11M
Total stockholder equity 32.29M 27.20M 24.31M 22.31M 23.22M
Common stock - 16.56M 16.51M 16.40M 16.32M
Capital stock 16.69M 16.56M 16.51M 16.40M 16.32M
Retained earnings 10.88M 5.96M 3.12M 1.26M 2.39M
Other liab - - 0.87M 0.38M 0.52M
Good will - - - - 0.00M
Other assets - 1.29M 1.56M 1.07M 1.22M
Cash 13.81M 7.78M 5.37M 1.86M 1.84M
Total current liabilities 2.10M 0.97M 1.39M 1.74M 1.36M
Short term debt - - - 0.18M 0.41M
Short long term debt - - 0.07M 0.18M 0.41M
Property plant equipment - 17.50M 18.59M 19.76M 17.95M
Total current assets 20.59M 11.73M 9.05M 6.41M 6.14M
Net tangible assets - 27.18M 24.29M 22.29M 23.19M
Net receivables 2.82M 2.14M 2.12M 3.71M 3.06M
Long term debt - - - 0.06M 0.23M
Inventory 3.76M 1.64M 1.21M 0.67M 0.71M
Accounts payable - 0.67M 1.05M 1.29M 0.95M
Non currrent assets other - - - 20.86M 19.19M
Non current assets total 17.15M 18.80M 20.17M 20.86M 19.19M
Capital lease obligations 2.62M 2.65M 2.90M 3.04M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.39M -0.79M -0.48M -0.20M -1.38M
Change to liabilities - -0.46M -0.36M 0.39M 0.10M
Total cashflows from investing activities - -0.79M -0.48M -0.20M -1.38M
Net borrowings - -0.33M -0.46M -0.69M -0.95M
Total cash from financing activities -0.22M -0.31M -0.46M -0.67M -0.83M
Change to operating activities - 0.17M -0.14M 0.15M -0.78M
Net income 4.40M 2.84M 1.86M -1.13M -0.32M
Change in cash 6.03M 2.41M 3.51M 0.01M -4.33M
Begin period cash flow 7.78M 5.37M 1.86M 1.84M 6.17M
End period cash flow 13.81M 7.78M 5.37M 1.86M 1.84M
Total cash from operating activities 6.64M 3.51M 4.45M 0.88M -2.12M
Depreciation 1.91M 1.70M 1.72M 1.82M 0.58M
Other cashflows from investing activities - -0.09M 0.13M 0.14M -0.13M
Change to inventory -1.43M -0.43M -0.54M 0.04M 0.37M
Change to account receivables -0.73M -0.07M 1.64M -0.64M -1.77M
Other cashflows from financing activities - - - - 0.12M
Change to netincome - -0.23M 0.28M 0.25M -0.32M
Capital expenditures 0.34M 0.71M 0.62M 0.34M 1.26M
Change in working capital -1.14M -0.80M 0.60M -0.06M -2.07M
Stock based compensation 0.09M 0.02M 0.14M 0.21M -
Other non cash items 0.13M 0.15M 0.18M 0.21M 0.06M
Free cash flow 6.30M 2.80M 3.83M 0.73M -3.38M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CZO
Ceapro		 0.12
1.97%		 6.21 - - 1.14 0.43 0.35 -2.63
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 - -
NRX
NurExone Biologic Inc.		 -0.01
2.00%		 0.49 - 6.90 - 15.26 - -7.24
MIR
MedMira Inc		 -
-%		 0.06 - - 223.37 - 293.42 -80.03
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17 - -58.16

Profile*

Ceapro

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

7824 ? 51 Avenue NW, Edmonton, AB, Canada, T6E 6W2

780 421 4555

https://www.ceapro.com

Name Title Year Born
Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc., MBA CEO, Pres & Director 1954
Ms. Stacy Prefontaine CPA, CA CFO & Corp. Sec. NA
Dr. Bernhard Seifried Sr. Director of Research & Technology NA
Ms. Sigrun Watson Chief Revenue Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…